SCHEMBL1224344

SCHEMBL1224344

Cc1nn(S(=O)(=O)c2ccc(Cl)cc2)c(C)c1Cc1c(Cl)cccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
ALDH1A1 P00352 3/20 0.46
POLB P06746 2/20 0.46
MAPK1 P28482 1/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.42
LMNA P02545 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MAPT P10636 3/20 0.41
ALOX12 P18054 1/20 0.41
THRB P10828 1/20 0.40
TP53 P04637 2/20 0.39
CYP2C19 P33261 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7058244 0.83 POLB (0.49) KMT2AMEN1ALDH1A1POLBPTGDR2
SCHEMBL4097692 0.80 PTGDR2 (0.51) KMT2AMEN1ALDH1A1POLBMAPK1
SCHEMBL17942372 0.70 POLB (0.52) KMT2AMEN1ALDH1A1POLBLMNA
SCHEMBL29596525 0.69 POLB (0.62) KMT2AMEN1ALDH1A1POLBMAPK1
SCHEMBL6341095 0.67 ENPP3 (0.43) ALDH1A1POLBLMNAGAA
SCHEMBL1224424 0.65 ENPP3 (0.54) KMT2AMEN1ALDH1A1POLBLMNA
SCHEMBL25257867 0.64 MEN1 (0.47) KMT2AMEN1ALDH1A1POLBMAPK1
SCHEMBL1779195 0.64 POLB (0.46) KMT2AMEN1ALDH1A1POLBLMNA
SCHEMBL29402620 0.64 MEN1 (0.47) KMT2AMEN1ALDH1A1POLBMAPK1
SCHEMBL1225318 0.63 GAA (0.45) KMT2AMEN1ALDH1A1MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193177-B2 Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases ANGION BIOMEDICA CORP. (US) 2012-06-05 US disclosed
US-7879898-B1 treating a chronic obstructive pulmonary disease using modulators of HGF/SF activity; for example, 3-(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)-1-(4-chlorophenyl)prop-2-en-1-one; emphysema ANGION BIOMEDICA CORP. (US) 2011-02-01 US disclosed
US-20100256117-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES ANGION BIOMEDICA CORP. 2010-10-07 US disclosed
US-20050096372-A1 Small-molecule modulators of hepatocyte growth factor/scatter factor activities PILLARISETTI SIVARAM (US) 2005-05-05 US disclosed
US-6855728-B2 Small-molecule modulators of hepatocyte growth factor / scatter factor activities NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM (US) 2005-02-15 US disclosed
US-20030216459-A1 Small-molecule modulators of hepatocyte growth factor / scatter factor activities THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 2003-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216459-A1 Small-molecule modulators of hepatocyte growth factor / scatter factor activities HGF, HDGF, MET KMT2A 4257/4885MEN1 3250/4885ALDH1A1 510/4885
US-20050096372-A1 Small-molecule modulators of hepatocyte growth factor/scatter factor activities HGF, HDGF, MET KMT2A 4257/4885MEN1 3250/4885ALDH1A1 510/4885
US-20100256117-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES HGF, HDGF, HGFAC KMT2A 3623/4885MEN1 2880/4885ALDH1A1 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.